Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 7/20 | 0.45 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044273 | 1.00 | NTSR1 (0.45) | NTSR1CASP1EIF4EBP1KDM4ERAB9A | |
| SCHEMBL27570420 | 0.89 | NTSR1 (0.46) | NTSR1EIF4EBP1KDM4ERAB9APSMB1 | |
| SCHEMBL311929 | 0.85 | NLRP3 (0.54) | NTSR1CASP1KDM4ERAB9APSMB1 | |
| SCHEMBL8344847 | 0.82 | CASP3 (0.41) | CASP1KDM4EPSMB1PSMB5NLRP3 | |
| SCHEMBL27589447 | 0.77 | KDM4E (0.44) | NTSR1EIF4EBP1KDM4ERAB9ANLRP3 | |
| SCHEMBL311998 | 0.73 | CASP1 (0.48) | CASP1 | |
| SCHEMBL312333 | 0.73 | PSMB5 (0.50) | CASP1KDM4EPSMB1PSMB5 | |
| SCHEMBL10044270 | 0.73 | KDM4E (0.55) | KDM4ERAB9AMEN1KMT2A | |
| SCHEMBL311997 | 0.73 | HDAC6 (0.47) | NTSR1CASP1PSMB1PSMB5 | |
| SCHEMBL311651 | 0.71 | MEN1 (0.43) | KDM4ERAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2308844-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308846-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308845-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7906650-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | NTSR1 2635/4885CASP1 1/4885EIF4EBP1 1309/4885 |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | NTSR1 2635/4885CASP1 1/4885EIF4EBP1 1309/4885 |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | NTSR1 2635/4885CASP1 1/4885EIF4EBP1 1309/4885 |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | NTSR1 2609/4885CASP1 1/4885EIF4EBP1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.